Chart: Inside JUPITER's Realm: A Closer Look At The Trial Results
Executive Summary
AstraZenenca's JUPITER study pushes the boundaries of the statin class to a new level. The latest large-scale outcomes trial for the statin class, using AstraZenenca's Crestor (rosuvastatin), explores use in a population that has healthy LDL cholesterol levels but with high levels of an inflammation biomarker that predicts future cardiovascular events: high-sensitivity C-reactive protein.